Cizzle Secures Canadian Patent to Fortify Global Lung Cancer Test Rollout

Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) has issued an announcement.

Canadian approval for Cizzle’s CIZ1B patent reinforces the company’s proprietary two-step lung cancer test, bolstering its licensing partner Cizzle Bio Inc’s commercial rollout in North America and supporting ambitions for broader global protection alongside expected U.S. grants. The strengthened intellectual property underpins Cizzle’s strategy to align with early-detection initiatives, particularly the NHS cancer plan, positioning the firm to deepen partnerships with clinical laboratories and hospitals and to safeguard shareholder value through exclusive technology deployment.

The most recent analyst rating on (GB:CIZ) stock is a Sell with a £1.50 price target. To see the full list of analyst forecasts on Cizzle Biotechnology Holdings PLC stock, see the GB:CIZ Stock Forecast page.

Spark’s Take on GB:CIZ Stock

According to Spark, TipRanks’ AI Analyst, GB:CIZ is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue, ongoing losses, cash burn, and a sharply reduced equity cushion), with technical indicators also pointing to subdued momentum. Valuation metrics provide limited support due to negative earnings and no dividend.

To see Spark’s full report on GB:CIZ stock, click here.

More about Cizzle Biotechnology Holdings PLC

Cizzle Biotechnology Holdings PLC develops non-invasive blood-based diagnostics centred on the CIZ1B biomarker for early-stage lung cancer, licensing its technology to partners across North America, the Caribbean, and other regions while targeting NHS-aligned expansion in the UK and Europe.

Average Trading Volume: 514,778

Technical Sentiment Signal: Strong Sell

Current Market Cap: £5.55M

For an in-depth examination of CIZ stock, go to TipRanks’ Overview page.